Ligand id: 8450

Name: ixazomib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 4
Rotatable bonds 9
Topological polar surface area 98.66
Molecular weight 360.08
XLogP 2.04
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

1. Bonvini P, Zorzi E, Basso G, Rosolen A. (2007)
Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma.
Leukemia, 21 (4): 838-42. [PMID:17268529]
2. Ciechanover A. (2005)
Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture).
Angew. Chem. Int. Ed. Engl., 44 (37): 5944-67. [PMID:16142822]
3. Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F et al.. (2010)
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Cancer Res., 70 (5): 1970-80. [PMID:20160034]
4. Richardson PG, Moreau P, Laubach JP, Gupta N, Hui AM, Anderson KC, San Miguel JF, Kumar S. (2015)
The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Future Oncol, 11 (8): 1153-68. [PMID:25832873]